Immune-related adverse events and the balancing act of immunotherapy COMMENT

被引：182

作者：

Conroy, Michael ^{[1
,2
,3
]}

Naidoo, Jarushka ^{[1
,2
,3
,4
]}

机构：

[1] Beaumont RCSI Canc Ctr, Dublin, Ireland

[2] Beaumont Hosp, Dublin, Ireland

[3] RCSI Univ Hlth Sci, Dublin, Ireland

[4] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21218 USA

来源：

NATURE COMMUNICATIONS | 2022年 / 13卷 / 01期

关键词：

PNEUMONITIS;

D O I：

10.1038/s41467-022-27960-2

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The benefit from immune checkpoint inhibitors is tempered by immunologic toxicities, which involve diverse organs, have varying biology, onset time, and severity. Herein, we identify important areas of controversy and open research questions in the field of immune-related toxicity.

引用

页数：4

共 20 条

[1] Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
Ali, Omar Hasan
Berner, Fiamma
Bomze, David
Fassler, Mirjam
Diem, Stefan
Cozzio, Antonio
Jorger, Markus
Fruh, Martin
Driessen, Christoph
Lenz, Tobias L.
Flatz, Lukas
[J]. EUROPEAN JOURNAL OF CANCER, 2019, 107 : 8 - 14
[2] Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
Arbour, Kathryn C.
Mezquita, Laura
Long, Niamh
Rizvi, Hira
Auclin, Edouard
Ni, Andy
Martinez-Bernal, Gala
Ferrara, Roberto
Lai, W. Victoria
Hendriks, Lizza E. L.
Sabari, Joshua K.
Caramella, Caroline
Plodkowski, Andrew J.
Halpenny, Darragh
Chaft, Jamie E.
Planchard, David
Riely, Gregory J.
Besse, Benjamin
Hellmann, Matthew D.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) : 2872 - +
[3] Balaji A, J IMMUNOTHER CANCER, V9
[4] Immortal Time Bias Question in the Association Between Toxicity and Outcome of Immune Checkpoint Inhibitors
Dall'Olio, Filippo G.
Di Nunno, Vincenzo
Massari, Francesco
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (01) : 105 - +
[5] Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo A Secondary Analysis of a Randomized Clinical Trial
Eggermont, Alexander M. M.
Kicinski, Michal
Blank, Christian U.
Mandala, Mario
Long, Georgina V.
Atkinson, Victoria
Dalle, Stephane
Haydon, Andrew
Khattak, Adnan
Carlino, Matteo S.
Sandhu, Shahneen
Larkin, James
Puig, Susana
Ascierto, Paolo A.
Rutkowski, Piotr
Schadendorf, Dirk
Koornstra, Rutger
Hernandez-Aya, Leonel
Di Giacomo, Anna Maria
van den Eertwegh, Alfonsus J. M.
Grob, Jean-Jacques
Gutzmer, Ralf
Jamal, Rahima
Lorigan, Paul C.
Krepler, Clemens
Ibrahim, Nageatte
Marreaud, Sandrine
van Akkooi, Alexander
Robert, Caroline
Suciu, Stefan
[J]. JAMA ONCOLOGY, 2020, 6 (04) : 519 - 527
[6] Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
Guidon, Amanda C.
Burton, Leeann B.
Chwalisz, Bart K.
Hillis, James
Schaller, Teilo H.
Amato, Anthony A.
Warner, Allison Betof
Brastianos, Priscilla K.
Cho, Tracey A.
Clardy, Stacey L.
Cohen, Justine, V
Dietrich, Jorg
Dougan, Michael
Doughty, Christopher T.
Dubey, Divyanshu
Gelfand, Jeffrey M.
Guptill, Jeffrey T.
Johnson, Douglas B.
Juel, Vern C.
Kadish, Robert
Kolb, Noah
LeBoeuf, Nicole R.
Linnoila, Jenny
Mammen, Andrew L.
Martinez-Lage, Maria
Mooradian, Meghan J.
Naidoo, Jarushka
Neilan, Tomas G.
Reardon, David A.
Rubin, Krista M.
Santomasso, Bianca D.
Sullivan, Ryan J.
Wang, Nancy
Woodman, Karin
Zubiri, Leyre
Louv, William C.
Reynolds, Kerry L.
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (07)
[7] Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Hodi, Frank Stephen
Chiarion-Sileni, Vanna
Gonzalez, Rene
Grob, Jean-Jacques
Rutkowski, Piotr
Cowey, Charles Lance
Lao, Christopher D.
Schadendorf, Dirk
Wagstaff, John
Dummer, Reinhard
Ferrucci, Pier Francesco
Smylie, Michael
Hill, Andrew
Hogg, David
Marquez-Rodas, Ivan
Jiang, Joel
Rizzo, Jasmine
Larkin, James
Wolchok, Jedd D.
[J]. LANCET ONCOLOGY, 2018, 19 (11) : 1480 - 1492
[8] Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
Maher, V. Ellen
Fernandes, Laura L.
Weinstock, Chana
Tang, Shenghui
Agarwal, Sundeep
Brave, Michael
Ning, Yang-min
Singh, Harpreet
Suzman, Daniel
Xu, James
Goldberg, Kirsten B.
Sridhara, Rajeshwari
Ibrahim, Amna
Theoret, Marc
Beaver, Julia A.
Pazdur, Richard
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (30) : 2730 - +
[9] A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events
Naidoo, Jarushka
Zhang, Jiajia
Lipson, Evan J.
Forde, Patrick M.
Suresh, Karthik
Moseley, Kendall F.
Mehta, Seema
Kwatra, Shawn G.
Parian, Alyssa M.
Kim, Amy K.
Probasco, John C.
Rouf, Rosanne
Thorne, Jennifer E.
Shanbhag, Satish
Riemer, Joanne
Shah, Ami A.
Pardoll, Drew M.
Bingham, Clifton O., III
Brahmer, Julie R.
Cappelli, Laura C.
[J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (06): : 712 - 720
[10] Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
Naidoo, Jarushka
Wang, Xuan
Woo, Kaitlin M.
Iyriboz, Tunc
Halpenny, Darragh
Cunningham, Jane
Chaft, Jamie E.
Segal, Neil H.
Callahan, Margaret K.
Lesokhin, Alexander M.
Rosenberg, Jonathan
Voss, Martin H.
Rudin, Charles M.
Rizvi, Hira
Hou, Xue
Rodriguez, Katherine
Albano, Melanie
Gordon, Ruth-Ann
Leduc, Charles
Rekhtman, Natasha
Harris, Bianca
Menzies, Alexander M.
Guminski, Alexander D.
Carlino, Matteo S.
Kong, Benjamin Y.
Wolchok, Jedd D.
Postow, Michael A.
Long, Georgina V.
Hellmann, Matthew D.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07) : 709 - +

← 1 2 →